<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002719</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06954</org_study_id>
    <secondary_id>EORTC-06954</secondary_id>
    <secondary_id>ITA-GIMEMA-AML13</secondary_id>
    <nct_id>NCT00002719</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number
      of immune cells found in the bone marrow or peripheral blood and may help a person's immune
      system recover after chemotherapy and radiation therapy. Combining more than one drug and
      giving drugs in different ways may kill more cancer cells.

      PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy
      with or without G-CSF in treating older patients with acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the role of granulocyte colony-stimulating factor given during and/or
      after remission induction with MICE (mitoxantrone/cytarabine/etoposide) in elderly patients
      with acute myelogenous leukemia (AML). II. Compare the complete remission (CR) rate and
      survival of these patients when treated with nearly equivalent doses of oral vs. intravenous
      mini-ICE (idarubicin/cytarabine/etoposide) as consolidation therapy given on an outpatient
      basis. III. Evaluate the feasibility of a second intensive consolidation regimen consisting
      of BAVC (carmustine/amsacrine/etoposide/cytarabine) followed by autologous stem cell support
      in patients under age 71 who are in CR and have good performance status.

      OUTLINE: Randomized study. All patients are randomly assigned to Arms IA through ID for
      Induction. Patients who achieve CR and who have adequate organ function and performance
      status are then randomly assigned to Arm IIA or IIB for Consolidation. At selected centers,
      patients in CR after their first Consolidation course who are under age 71 and in very good
      clinical condition are treated on Regimen A (in lieu of a second Consolidation course). The
      following acronyms are used: AMSA Amsacrine, NSC-249992 ARA-C Cytarabine, NSC-63878 BAVC
      BCNU/AMSA/VP-16/ARA-C BCNU Carmustine, NSC-409962 DHAD Mitoxantrone, NSC-301739 G-CSF
      Granulocyte Colony-Stimulating Factor (Rhone-Poulenc Rorer) IDA Idarubicin, NSC-256439 MICE
      DHAD/ARA-C/VP-16 Mini-ICE IDA/ARA-C/VP-16 PBSC Peripheral Blood Stem Cells VP-16 Etoposide,
      NSC-141540 INDUCTION: Arm IA: 3-Drug Combination Chemotherapy. MICE. Arm IB: 3-Drug
      Combination Chemotherapy plus Hematologic Toxicity Attenuation. MICE; plus G-CSF. G-CSF
      during chemotherapy. Arm IC: 3-Drug Combination Chemotherapy plus Hematologic Toxicity
      Attenuation. MICE; plus G-CSF. G-CSF after chemotherapy. Arm ID: 3-Drug Combination
      Chemotherapy plus Hematologic Toxicity Attenuation. MICE; plus G-CSF. G-CSF during and after
      chemotherapy. CONSOLIDATION: Arm IIA: 3-Drug Combination Chemotherapy. Mini-ICE. Intravenous
      IDA/VP-16/ARA-C. Arm IIB: 3-Drug Combination Chemotherapy. Mini-ICE. Oral IDA/VP-16 +
      subcutaneous ARA-C. Regimen A: Stem Cell Mobilization followed by 4-Drug Combination
      Myeloablative Chemotherapy with Stem Cell Rescue. G-CSF; followed by BAVC; with PBSC.

      PROJECTED ACCRUAL: 500 patients will be randomized for Induction, of whom an anticipated 238
      patients will be randomized for Consolidation. If at interim analyses survival is shorter on
      Regimen A, that regimen will be closed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1995</start_date>
  <primary_completion_date type="Actual">November 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Leukemia</condition>
  <condition>Neutropenia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amsacrine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute myeloblastic leukemia (AML) At least 30% blast cells in bone
        marrow smear Secondary AML eligible, as follows: Secondary to myelodysplastic syndrome (but
        not other myeloproliferative diseases) Secondary to cured Hodgkin's disease or other cured
        malignancy Secondary to alkylating agents or radiation for other reasons Acute
        promyelocytic leukemia (M3) referred to the collaborative Gruppo Italiano Malattie
        Ematologiche Maligne dell'Adulto-EORTC protocol (EORTC-06952) No blast crisis of chronic
        myeloid leukemia

        PATIENT CHARACTERISTICS: Age: 61 to 80 Performance status: WHO 0-2 Life expectancy: No
        marked impairment from disease other than AML Hematopoietic: Not applicable Hepatic:
        Bilirubin less than 2 x ULN Renal: Creatinine less than 2 x ULN Cardiovascular: LVEF at
        least 50% No severe cardiac disease Pulmonary: No severe pulmonary disease Other: HIV
        seronegative (if tested) No uncontrolled infection No severe neurologic, metabolic, or
        psychiatric disease No other concomitant disease that precludes protocol therapy No other
        progressive malignant disease

        PRIOR CONCURRENT THERAPY: No prior chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roel Willemze, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Mandelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Policlinico Umberto Primo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto Primo</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica. 2007 Mar;92(3):389-96.</citation>
    <PMID>17339189</PMID>
  </results_reference>
  <results_reference>
    <citation>Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefr√®re F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T; EORTC/GIMEMA Leukemia Group. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005 Jul 1;106(1):27-34. Epub 2005 Mar 10.</citation>
    <PMID>15761020</PMID>
  </results_reference>
  <results_reference>
    <citation>Jehn U, Suciu S, Thomas X, et al.: Oral vs intravenous consolidation chemotherapy in elderly patients with AML. Results of the EORTC-GIMEMA AML-13 phase III trial. [Abstract] Blood 100 (11 Pt 1): A-319, 87a, 2002.</citation>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2004</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>neutropenia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Amsacrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

